Roche has decided to stop recruitment for their Phase 2 SHIELD DMD study of satralizumab in Duchenne, citing the decision was not due to any new efficacy or safety issues, but rather due to feasibility concerns with meeting regulatory requirements, as well as recruitment and study completion deadlines.
Please see the community letter for more information, including next steps for study participants and individuals who are currently screening to participate. Roche plans to continue the study through the 6-month bone density data collection, which is expected in H2 2026.
We recognize that it is difficult news for the community anytime a study is discontinued, and want to thank all of the families who have been participating in this study.
The post Roche stopping bone health program in Duchenne appeared first on CureDuchenne.